Pharmaceuticals

TRAD CHI MED

TRAD CHI MED released FY2025 9 Months Earnings on March 20 (BJT), actual revenue HKD 12.06 B, actual EPS HKD -0.0485

TRAD CHI MED released FY2025 Q3 earnings on March 20, 2026 (BJT), with actual revenue of HKD 3.98 B and EPS of HKD -0.0254

TRAD CHI MED released FY2025 earnings on March 20 During-Market (BJT), actual revenue HKD 16.12 B (forecast HKD 16.35 B), actual EPS HKD -0.0742 (forecast HKD 0.0111)

TRAD CHI MED released FY2025 Q4 earnings on March 20 During-Market (BJT), actual revenue HKD 4.049 B, actual EPS HKD -0.0258

TRAD CHI MED to release FY2025 earnings on March 20 During-Market (BJT), forecast revenue HKD 16.51 B, EPS HKD 0.0112

CICC Maintains Neutral Rating on China National Medicines with a Target Price of HKD 2.40

TRAD CHI MED released FY2025 Q1 earnings on August 29 (BJT), actual revenue HKD 3.997 B, actual EPS HKD -0.0114

China National Medicinal Corporation Inc. Reports a Mid-Year Loss of 108 Million Yuan and a 11% Drop in Revenue

TRAD CHI MED released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue HKD 4.084 B, actual EPS HKD -0.0117

TRAD CHI MED released FY2025 Semi-Annual Earnings on August 29 During-Market (BJT), Actual Revenue: HKD 8.081 B, Actual EPS: HKD -0.0232

TRAD CHI MED FY2025 Semi-Annual Earnings Release on August 29, 2025 (BJT)

Morgan Stanley Downgrades China National Medicinal Rating

China National Medicines Corp Expecting Net Profit to Decline by 165% to 175%

Morgan Stanley Downgrades China National Medicinal's Earnings Forecast and Target Price

China National Medicines Corporation's Affiliated Company's Yu Shuda Tablets Registration Application Accepted by National Medical Products Administration

China 中药 Non-Executive Directors' Positions Adjusted

China National Medicines Corp to Replace Auditor Due to Regulatory Requirements

China National Medicines Announces Special Dividend for 2025

China 中药 Announces Final Dividend of HKD 0.0035 per Share

China National Medicines Appoints New Vice President Zheng Jun

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

00570

516930

588130

510660

02841

159316

159506

Yesterday's closing price for China Traditional Chinese Medicine rose slightly by 1.19%, with a trading volume of approximately HKD 92 million, which is a slight increase compared to usual, reflecting the market's attention to its mid-term development prospects. The MACD daily line has not yet formed a clear strong bullish signal, but the latest dynamics in the electronic chemical pharmaceutical sector provide good visibility for it. Under the influence of news, the government's support for the traditional Chinese medicine industry is evident. With the continuous expansion of domestic healthcare demand and the increasing awareness of healthy living, the demand potential in the traditional Chinese medicine market is gradually being released. The company is further enhancing its market competitiveness through continuous research and development, innovation initiatives, and the expansion of its market network. Technically, the stock price trend remains stable above the mid-line trend level, reflecting that short-term positions are still primarily focused on position management. As market sentiment gradually recovers, if downward resistance diminishes, we can expect more significant liquidity changes and a positive drive for the market to refocus on the traditional Chinese medicine concept. The short-term trend is positively referenced, especially with the support of favorable industry prospects, traditional Chinese medicine concept stocks are not afraid of short-term market fluctuations. Caution is needed regarding the impact of the board's substantive decisions on stock prices, as well as the potential chain reaction from important economic indicators exceeding expectations. This article provides only technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances

Technical Forecast

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal 800 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

GF CSI All Share Health Care ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI HK Equities Medical and Health Integration ETF

GX CN MEDTECH

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Guotai SSE STAR Brand Name Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Pre-market trend | China Traditional Chinese Medicine (0570.HK) slightly warmed up on May 7, is there a hint of spring for the TCM concept?

01666

03613

Recently, the National Chinese Herbal Pieces Alliance Procurement Office released centralized procurement documents, proposing to purchase 41 varieties of Chinese herbal pieces, categorized into two specification grades: selected goods and unified goods. This procurement follows the principles of 'stabilizing clinical use, ensuring quality, opposing internal competition, and preventing bid rigging,' led by the Shandong Medical Security Bureau, and is expected to reshape a market valued at 300 billion yuan

Wallstreetcn

TONG REN TANG

TONGRENTANGCM

CR Sanjiu

Taikang CNI Public Health and Medical Health ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to Change

TRAD CHI MED announced its performance for the fiscal year 2025, with a revenue of 14.745 billion RMB, a year-on-year decrease of 10.7%. It recorded a loss of 342 million RMB, compared to a net profit of 54.07 million RMB in the previous year, turning from profit to loss; the loss per share is 6.79 cents. No final dividend will be distributed

AASTOCKS

"Performance" TRAD CHI MED reported a full-year loss of 342 million RMB, turning from profit to loss

China Traditional Chinese Medicine Holdings Co (HK:0570) has scheduled a board meeting for March 20, 2026, to approve its consolidated final results for the year ending December 31, 2025, and to consider declaring a final dividend. This decision may impact shareholder returns and reflect management's assessment of the company's financial performance. The board consists of 12 members, including executive and independent directors. Analysts currently rate the stock as a Hold with a price target of HK$2.00. The company focuses on traditional Chinese medicine and related healthcare services.

Tip Ranks

China TCM Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend

China Traditional Chinese Medicine Holdings Co. Limited has received shareholder approval for its 2026–2028 Financial Services Framework Agreement and new Master Purchase and Supply Agreements during an extraordinary general meeting on February 2, 2026. Despite major shareholder CNPGC abstaining from voting, the resolutions were passed with around 99% approval, ensuring operational continuity and compliance with Hong Kong listing requirements. The current analyst rating for the stock (HK:0570) is a Hold with a price target of HK$2.00, and the company has a market cap of HK$10.37B.

China TCM Wins Shareholder Approval for 2026–2028 Financial, Purchase and Supply Frameworks

Morgan Stanley expects the stock price of TRAD CHI MED to decline within the next 30 days, with a probability of 70% to 80%. The firm has adjusted its rating to "Underweight" and set a target price of 1.5 yuan. The reason is that the company is expected to record a loss in the fiscal year 2025 and has not disclosed specific market expansion plans, leading to low visibility on the 2026 performance, with expectations that the stock price still has downside potential

Morgan Stanley expects that the stock price of China Traditional Chinese Medicine will decline in the next 30 days

China Traditional Chinese Medicine opened 1.83% lower this morning (28th), with a lowest price of 2.07 yuan. In the early stage, it was last reported at 2.11 yuan, down 3.65%, with a trading volume of 11.766 million shares, involving 24.8037 million yuan. The company issued a profit warning, expecting a loss of between 350 million and 500 million yuan for the fiscal year 2025, compared to a profit of 20.77 million yuan in the previous year; the adjusted net profit is expected to decline by 45% to 55%

TRAD CHI MED fell 3.7% in the early stage, expected to have a maximum loss of 500 million RMB last year

TRAD CHI MED(00570.HK)